Perinatal hepatitis B is the chronic hepatitis B virus infection transmitted from mother to child, predominantly via vertical transmission during pregnancy or the perinatal period [1]. It is a major contributor to the global reservoir of chronic HBV infection [1].
Aperçu de la maladie
Informations étayées par des preuves EN 5/7 sections · FR 5/7 sections Mis à jour le Oct 23, 2026
Perinatal hepatitis B refers to chronic HBV infection acquired through mother-to-child transmission, which constitutes the majority of chronic HBV cases worldwide [1]. It remains a global health burden with ongoing endemic persistence and significant morbidity and mortality [1]. Pregnancy represents a key intervention window for eliminating this transmission route through offspring immunization and maternal management [1].
Lire le profil clinique et épidémiologique complet 6
Infants affected by perinatal transmission may test positive for hepatitis B surface antigen at birth or at six months of age, indicating established infection [2]. The condition manifests as chronic HBV infection rather than acute illness in the newborn period [1][2].
Chronic HBV infection from perinatal transmission is endemic globally and accounts for the majority of chronic HBV cases, representing a leading source of long-term morbidity and mortality [1]. The World Health Organization has set a 2030 eradication target, with vertical transmission recognized as the principal driver of persistent infection burden [1].
The primary mode of perinatal hepatitis B is vertical transmission from mother to child, responsible for most chronic HBV infections [1]. High maternal viremia increases the risk of immunoprophylaxis failure and persistent infection in the newborn [1].
Routine antenatal screening of pregnant women and neonatal immunoprophylaxis are the central measures to reduce perinatal HBV transmission [1]. Timely newborn vaccination is essential, and highly viremic mothers may receive antenatal antiviral treatment to prevent immunoprophylaxis failure [1]. Tenofovir alafenamide fumarate during pregnancy was as effective as other antivirals in lowering mother-to-child transmission rates without adverse infant outcomes [2].
- 1 Cheung KW et al. Prevention of perinatal hepatitis B virus transmission. Arch Gynecol Obstet. 2019 Aug. PMID: 31098821. doi: 10.1007/s00404-019-05190-0. PubMed: https://pubmed.ncbi.nlm.nih.gov/31098821/
- 2 Huang J et al. Effectiveness and Safety of Tenofovir Alafenamide Fumarate in the Prevention of Perinatal Hepatitis B Transmission: A Meta-Analysis. Dig Dis Sci. 2024 Mar. PMID: 38341392. doi: 10.1007/s10620-023-08258-9. PubMed: https://pubmed.ncbi.nlm.nih.gov/38341392/
Chargement des données actuelles…
Tendances nationales
Choisissez le pays, la source et la mesure ; chaque courbe conserve sa période et sa définition de déclaration.
Chargement des données…
Couverture des données
Pays et régions déclarants
La carte montre la couverture déclarée. Choisissez une mesure ou ouvrez un lieu coloré pour consulter ses données.
Chargement des données actuelles…
Profil de surveillance
Saisonnalité du pays sélectionné
Consultez les valeurs mensuelles d’un pays par année. Les cases vides indiquent une valeur non publiée.
Radar de recherche
Recherches récentes associées
Hepatitis B vaccine stored outside the cold chain setting: a pilot study in rural Lao PDR
Vaccine
Évalué par les pairs Accès ouvert Association forte à la maladie Hépatite B périnatale Dynamique de transmission
DOI 10.1016/j.vaccine.2012.10.079 ↗ Using data to guide policy: Next steps for preventing perinatal hepatitis B virus transmission in Cambodia
Vaccine
Les liens bibliographiques servent à découvrir des travaux et ne modifient ni ne valident la série de surveillance ci-dessus.
Chargement des alertes officielles…
Téléchargement et méthodes
Choisissez une période et téléchargez les fichiers CSV, JSON ou XLSX.